In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...